New hope for lymphoma patients as First-in-Human drug trial begins
NCT ID NCT07439653
Summary
This is the first study in people to test a new drug called TORL-5-700 for B-cell Non-Hodgkin Lymphoma that has come back or not responded to other treatments. The main goals are to find a safe dose and see if the drug can shrink tumors, both on its own and when combined with other medications. The study will enroll about 155 adults with specific types of B-cell lymphoma who have at least one measurable tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTOLOGICALLY CONFIRMED RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.